Tracking extranigral degeneration in animal models of Parkinson's disease: Quest for effective therapeutic strategies

Journal of Neurochemistry

Volumn 118, Issue 3, 2011, Pages 326-338

  Knaryan, Varduhi H ^a   Samantaray, Supriti ^a   Le Gal, Charlene ^b   Ray, Swapan K ^c   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

animal models; extranigral degeneration; Parkinson's disease; spinal cord degeneration

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; DOPAMINE; LEVODOPA; LIPOPOLYSACCHARIDE; MANEB; PARAQUAT; PROLINE; ROTENONE; THREONINE; TYROSINE 3 MONOOXYGENASE;

ALPHA SYNUCLEIN GENE; DISEASE COURSE; DISEASE MODEL; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; ELECTROSTIMULATION THERAPY; EXTRAPYRAMIDAL SYMPTOM; GENE; GENE MUTATION; IN VIVO STUDY; LEWY BODY; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SPINAL CORD ATROPHY; SPINAL CORD NERVE CELL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; SYMPTOM;

ANIMALS; ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MICE; NERVE DEGENERATION; PARKINSON DISEASE; PRIMATES; RATS; SPINAL CORD; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 79960331575     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07320.x     Document Type: Review

References (134)

1. Alerte T. N., Akinfolarin A. A., Friedrich E. E., Mader S. A., Hong C. S., and, Perez R. G., (2008) Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett. 435, 24-29.
2. Berendse H. W., and, Ponsen M. M., (2009) Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat. Disord. 15 (Suppl 3), S26-S30.
3. Bing G., Zhang Y., Watanabe Y., McEwen B. S., and, Stone E. A., (1994) Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668, 261-265.
4. Bloch A., Probst A., Bissig H., Adams H., and, Tolnay M., (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 32, 284-295.
5. von Bohlen und Halbach O., Schober A., Hertel R., and, Unsicker K., (2005) MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala. Neurodegener. Dis. 2, 44-48. (Pubitemid 41158939)
6. Braak H., and, Braak E., (2000) Pathoanatomy of Parkinson's disease. J. Neurol. 247 (Suppl 2), II3-II10.
7. Braak H., and, Del Tredici K., (2008) Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916-1925. (Pubitemid 351684646)
8. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R. A., and, Jansen E. N., (1995) Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl. 46, 15-31. (Pubitemid 26043220)
9. Braak H., Braak E., Yilmazer D., de Vos R. A., Jansen E. N., and, Bohl J., (1996) Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J. Neural Transm. 103, 455-490.
10. Braak H., Rub U., and, Braak E., (2000) Neuroanatomy of Parkinson disease. Changes in the neuronal cytoskeleton of a few disease-susceptible types of neurons lead to progressive destruction of circumscribed areas in the limbic and motor systems. Nervenarzt 71, 459-469. (Pubitemid 30434514)
11. Braak H., Del Tredici K., Rub U., de Vos R. A., Jansen Steur E. N., and, Braak E., (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. (Pubitemid 36007810)
12. Braak H., Sastre M., Bohl J. R., de Vos R. A., and, Del Tredici K., (2007) Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 113, 421-429. (Pubitemid 46421631)
13. Chadha A., Dawson L. G., Jenner P. G., and, Duty S., (2000) Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience 95, 119-126.
14. Chen Q., Andersen A. H., Zhang Z., Ovadia A., Cass W. A., Gash D. M., and, Avison M. J., (1999) Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Exp. Neurol. 158, 63-75. (Pubitemid 29344318)
15. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Ray S. K., Ali S. F., and, Banik N. L., (2002) Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. Ann. N Y Acad. Sci. 965, 274-280. (Pubitemid 34721975)
16. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Sribnick E. A., Ray S. K., Ali S. F., and, Banik N. L., (2004) Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Brain Res. 1006, 150-156. (Pubitemid 38393759)
17. Choi Y. G., Park J. H., and, Lim S., (2009) Acupuncture inhibits ferric iron deposition and ferritin-heavy chain reduction in an MPTP-induced parkinsonism model. Neurosci. Lett. 450, 92-96.
18. Choi Y. G., Yeo S., Hong Y. M., Kim S. H., and, Lim S., (2011) Changes of gene expression profiles in the cervical spinal cord by acupuncture in an MPTP-intoxicated mouse model: microarray analysis. Gene 481, 7-16.
19. Cohen R. M., Carson R. E., Wyatt R. J., and, Doudet D. J., (1999) Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. Synapse 33, 282-288. (Pubitemid 29381935)
20. Cole D. G., Growdon J. H., and, DiFiglia M., (1993) Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Exp. Neurol. 120, 223-232. (Pubitemid 23165017)
21. Defazio G., Berardelli A., Fabbrini G., et al. (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch. Neurol. 65, 1191-1194.
22. Dickson D. W., Braak H., Duda J. E., et al. (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150-1157.
23. Fernandez-Ruiz J., Guzman R., Martinez M. D., Miranda M. I., Bermudez-Rattoni F., and, Drucker-Colin R., (1993) Adrenal medullary grafts restore olfactory deficits and catecholamine levels of 6-OHDA amygdala lesioned animals. J. Neural Transplant. Plast. 4, 289-297. (Pubitemid 24221443)
24. Forno L. S., (1987) The Lewy body in Parkinson's disease. Adv. Neurol. 45, 35-43.
25. Forno L. S., Langston J. W., DeLanney L. E., Irwin I., and, Ricaurte G. A., (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20, 449-455. (Pubitemid 16005662)
26. Fournier M., Vitte J., Garrigue J., et al. (2009) Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS ONE 4, e6629.
27. Franco J., Prediger R. D., Pandolfo P., Takahashi R. N., Farina M., and, Dafre A. L., (2007) Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. Life Sci. 80, 1906-1914. (Pubitemid 46560734)
28. Freichel C., Neumann M., Ballard T., et al. (2007) Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 28, 1421-1435. (Pubitemid 47081234)
29. Fuentes R., Petersson P., Siesser W. B., Caron M. G., and, Nicolelis M. A., (2009) Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science 323, 1578-1582.
30. Fuentes R., Petersson P., and, Nicolelis M. A., (2010) Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. Eur. J. Neurosci. 32, 1100-1108.
31. Gao Z., Liu Y., and, Wei X., (1998) A pathological study on the autotransplantation of monkey's cervical sympathetic ganglion into brain for the treatment of Parkinson's disease. Zhonghua Bing Li Xue Za Zhi 27, 113-116.
32. Garvey J., Petersen M., Waters C. M., Rose S. P., Hunt S., Briggs R., Jenner P., and, Marsden C. D., (1986) Administration of MPTP to the common marmoset does not alter cortical cholinergic function. Mov. Disord. 1, 129-134.
33. Gibb W. R., and, Lees A. J., (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol. Appl. Neurobiol. 15, 27-44. (Pubitemid 19074096)
34. Gibb W. R., Mountjoy C. Q., Mann D. M., and, Lees A. J., (1989a) A pathological study of the association between Lewy body disease and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 52, 701-708. (Pubitemid 19165634)
35. Gibb W. R., Terruli M., Lees A. J., Jenner P., and, Marsden C. D., (1989b) The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov. Disord. 4, 53-74. (Pubitemid 19037948)
36. Gu X. L., Long C. X., Sun L., Xie C., Lin X., and, Cai H., (2011) Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain 3, 12.
37. Henderson J. M., Schleimer S. B., Allbutt H., Dabholkar V., Abela D., Jovic J., and, Quinlivan M., (2005) Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism. Behav. Brain Res. 162, 222-232. (Pubitemid 40828534)
38. Herting B., Bietenbeck S., Scholz K., Hähner A., Hummel T., and, Reichmann H., (2008) Olfactory dysfunction in Parkinson's disease: its role as a new cardinal sign in early and differential diagnosis. Nervenarzt 79, 175-184. (Pubitemid 351229654)
39. Hoglinger G. U., Feger J., Prigent A., Michel P. P., Parain K., Champy P., Ruberg M., Oertel W. H., and, Hirsch E. C., (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502. (Pubitemid 36182248)
40. Hornykiewicz O., (2008) Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener. Dis. 5, 114-117. (Pubitemid 351347826)
41. Huang C. C., and, Lee E. H., (1995) Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats. J. Neurosci. Res. 41, 471-480.
42. Itakura T., Kamei I., Nakai K., Naka Y., Nakakita K., Imai H., and, Komai N., (1988) Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. J. Neurosurg. 68, 955-959.
43. Jellinger K. A., (1999) Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 56, 1-29.
44. Jellinger K. A., (2009) Formation and development of Lewy pathology: a critical update. J. Neurol. 256 (Suppl 3), 270-279.
45. Jenkins B. G., Sanchez-Pernaute R., Brownell A. L., Chen Y. C., and, Isacson O., (2004) Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 24, 9553-9560. (Pubitemid 39441509)
46. Jouve L., Salin P., Melon C., and, Kerkerian-Le Goff L., (2010) Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease. J. Neurosci. 30, 9919-9928.
47. Kalaitzakis M. E., Graeber M. B., Gentleman S. M., and, Pearce R. K., (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol. 116, 125-128; author reply 129-131.
48. Kalaitzakis M. E., Graeber M. B., Gentleman S. M., and, Pearce R. K., (2009) Parkinson disease: extranigral, multisystem, and {alpha}-synuclein "plus". Arch. Neurol. 66, 914-915; author reply 915-916.
49. Kamo H., Kim S. U., McGeer P. L., and, Shin D. H., (1986) Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons. Brain Res. 397, 372-376.
50. Kang J. M., Park H. J., Choi Y. G., Choe I. H., Park J. H., Kim Y. S., and, Lim S., (2007) Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res. 1131, 211-219. (Pubitemid 46053895)
51. Kerkerian-Le Goff L., Bacci J. J., Jouve L., Melon C., and, Salin P., (2009) Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease. Brain Res. Bull. 78, 80-84.
52. Klos K. J., Josephs K. A., Parisi J. E., and, Dickson D. W., (2005) Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease. Mov. Disord. 20, 1515-1520. (Pubitemid 43072663)
53. Klos K. J., Ahlskog J. E., Josephs K. A., Apaydin H., Parisi J. E., Boeve B. F., DeLucia M. W., and, Dickson D. W., (2006) Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66, 1100-1102. (Pubitemid 44044801)
54. Lane E., and, Dunnett S., (2008) Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) 199, 303-312. (Pubitemid 351938234)
55. Langston J. W., (2006) The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591-596.
56. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., and, Baekelandt V., (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13, 364-372. (Pubitemid 36975826)
57. Lee M. K., Stirling W., Xu Y., et al. (2002) Human alpha-synuclein- harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968-8973. (Pubitemid 34693667)
58. Lim S. Y., Fox S. H., and, Lang A. E., (2009) Overview of the extranigral aspects of Parkinson disease. Arch. Neurol. 66, 167-172.
59. Lin F. K., Xin Y., Gao D. M., Xiong Z., and, Chen J. G., (2007) [Effects of electrical stimulation of the parafascicular nucleus on the neuronal activities of the subthalamic nucleus and the ventromedial nucleus in rats]. Sheng Li Xue Bao 59, 79-85.
60. Lin C. H., Huang J. Y., Ching C. H., and, Chuang J. I., (2008) Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res. 44, 205-213.
61. Liu B., and, Xie J., (2004) Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats. J. Neurochem. 90, 654-658. (Pubitemid 38989396)
62. Lyden A., Bondesson U., Larsson B. S., Lindquist N. G., and, Olsson L. I., (1985) Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues. Acta Pharmacol. Toxicol. (Copenh) 57, 130-135. (Pubitemid 15226504)
63. Marin C., Aguilar E., and, Bonastre M., (2008) Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats. J. Neural Transm. 115, 1133-1139.
64. Martin L. J., Pan Y., Price A. C., Sterling W., Copeland N. G., Jenkins N. A., Price D. L., and, Lee M. K., (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50. (Pubitemid 43089519)
65. Mavridis M., Degryse A. D., Lategan A. J., Marien M. R., and, Colpaert F. C., (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507-523.
66. Melrose H. L., Lincoln S. J., Tyndall G. M., and, Farrer M. J., (2006) Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 173, 196-204. (Pubitemid 44264883)
67. Melrose H. L., Kent C. B., Taylor J. P., et al. (2007) A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147, 1047-1058. (Pubitemid 47102551)
68. Mendritzki S., Schmidt S., Sczepan T., Zhu X.-R., Segelcke D., and, Lubbert H., (2010) Spinal cord pathology in alpha-synuclein transgenic mice. Parkinson's Disease 2010, 375462.
69. Meredith G. E., Sonsalla P. K., and, Chesselet M. F., (2008) Animal models of Parkinson's disease progression. Acta Neuropathol. 115, 385-398.
70. Miguelez C., Grandoso L., and, Ugedo L., (2011) Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol. 14, 187-200.
71. Mizobuchi M., Hineno T., Kakimoto Y., and, Hiratani K., (1993) Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated dogs. Brain Res. 612, 319-321. (Pubitemid 23167297)
72. Morris J. C., Drazner M., Fulling K., Grant E. A., and, Goldring J., (1989) Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch. Neurol. 46, 651-657. (Pubitemid 19150944)
73. Muhlack S., Konietzka S., Woitalla D., Przuntek H., and, Müller T., (2004) Simple movement sequences better correlate to levodopa plasma levels than complex ones. J. Neural Transm. Suppl. 68, 53-60. (Pubitemid 39215437)
74. Müller T., Kuhn W., Büttner T., Eising E., Coenen H., Haas M., and, Przuntek H., (1998) Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J. Neurol. 245, 659-664. (Pubitemid 28439031)
75. Murphy K. E., Karaconji T., Hardman C. D., and, Halliday G. M., (2008) Excessive dopamine neuron loss in progressive supranuclear palsy. Mov. Disord. 23, 607-610.
76. Nakai M., Itakura T., Kamei I., Nakai K., Naka Y., Imai H., and, Komai N., (1990) Autologous transplantation of the superior cervical ganglion into the brain of parkinsonian monkeys. J. Neurosurg. 72, 91-95. (Pubitemid 20027304)
77. Nakamura S., and, Vincent S. R., (1986) Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+. Neurosci. Lett. 65, 321-325. (Pubitemid 16109659)
78. Nakao N., Itakura T., Uematsu Y., and, Komai N., (1995) Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: survival and function of graft. Acta Neurochir. (Wien) 133, 61-67.
79. Nakao N., Shintani-Mizushima A., Kakishita K., and, Itakura T., (2004) The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. Exp. Neurol. 188, 65-73. (Pubitemid 38748805)
80. Neumann M., Kahle P. J., Giasson B. I., et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429-1439. (Pubitemid 35396914)
81. Nowak P., Noras L., Jochem J., Szkilnik R., Brus H., Korossy E., Drab J., Kostrzewa R. M., and, Brus R., (2009) Histaminergic activity in a rodent model of Parkinson's disease. Neurotox. Res. 15, 246-251.
82. O'Neill J., Schuff N., Marks Jr W. J., Feiwell R., Aminoff M. J., and, Weiner M. W., (2002) Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov. Disord. 17, 917-927. (Pubitemid 36040996)
83. Orieux G., Francois C., Feger J., Yelnik J., Vila M., Ruberg M., Agid Y., and, Hirsch E. C., (2000) Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97, 79-88. (Pubitemid 30195878)
84. Oueslati A., Breysse N., Amalric M., Kerkerian-Le Goff L., and, Salin P., (2005) Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur. J. Neurosci. 22, 2765-2774. (Pubitemid 41811273)
85. Pahapill P. A., and, Lozano A. M., (2000) The pedunculopontine nucleus and Parkinson's disease. Brain 123 (Pt 9), 1767-1783. (Pubitemid 30664282)
86. Pallini R., Fernandez E., Lauretti L., et al. (1996) Superior cervical ganglion regenerating axons through peripheral nerve grafts and reversal of behavioral deficits in hemiparkinsonian rats. J. Neurosurg. 84, 487-493. (Pubitemid 26062876)
87. Parr-Brownlie L. C., Poloskey S. L., Flanagan K. K., Eisenhofer G., Bergstrom D. A., and, Walters J. R., (2007) Dopamine lesion-induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats. Eur. J. Neurosci. 26, 1925-1939. (Pubitemid 47493198)
88. Parr-Brownlie L. C., Poloskey S. L., Bergstrom D. A., and, Walters J. R., (2009) Parafascicular thalamic nucleus activity in a rat model of Parkinson's disease. Exp. Neurol. 217, 269-281.
89. Pierantozzi M., Palmieri M. G., Galati S., et al. (2008) Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients. J. Neural Transm. 115, 731-735.
90. Poewe W., (2009) Clinical measures of progression in Parkinson's disease. Mov. Disord. 24 (Suppl 2), S671-S676.
91. Poewe W., and, Mahlknecht P., (2009) The clinical progression of Parkinson's disease. Parkinsonism Relat. Disord. 15 (Suppl 4), S28-S32.
92. Probst A., Bloch A., and, Tolnay M., (2008) New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur. J. Neurol. 15 (Suppl 1), 1-4. (Pubitemid 351421305)
93. Przuntek H., Muller T., and, Riederer P., (2004) Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural Transm. 111, 201-216. (Pubitemid 38283231)
94. Ray S. K., Wilford G. G., Ali S. F., and, Banik N. L., (2000) Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced Parkinson's disease. Ann. N Y Acad. Sci. 914, 275-283.
95. Rolland A. S., Herrero M. T., Garcia-Martinez V., Ruberg M., Hirsch E. C., and, Francois C., (2007) Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism. Brain 130, 265-275. (Pubitemid 46026241)
96. Rommelfanger K. S., Edwards G. L., Freeman K. G., Liles L. C., Miller G. W., and, Weinshenker D., (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl Acad. Sci. USA 104, 13804-13809. (Pubitemid 350003401)
97. Sage J. I., Kortis H. I., and, Sommer W., (1990) Evidence for the role of spinal cord systems in Parkinson's disease-associated pain. Clin. Neuropharmacol. 13, 171-174. (Pubitemid 20109361)
98. Samantaray S., Ray S. K., Ali S. F., and, Banik N. L., (2006) Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism. Ann. N Y Acad. Sci. 1074, 349-356. (Pubitemid 44532839)
99. Samantaray S., Knaryan V. H., Guyton M. K., Matzelle D. D., Ray S. K., and, Banik N. L., (2007) The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146, 741-755. (Pubitemid 46656209)
100. Samantaray S., Butler J. T., Ray S. K., and, Banik N. L., (2008a) Extranigral neurodegeneration in Parkinson's disease. Ann. N Y Acad. Sci. 1139, 331-336.
101. Samantaray S., Knaryan V. H., Butler J. T., Ray S. K., and, Banik N. L., (2008b) Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. J. Neurochem. 104, 1309-1320. (Pubitemid 351293347)
102. Samantaray S., Ray S. K., and, Banik N. L., (2008c) Calpain as a potential therapeutic target in Parkinson's disease. CNS Neurol. Disord. Drug Targets 7, 305-312.
103. Sandyk R., Iacono R. P., and, Kay S. R., (1990) The hypothalamus in MPTP-induced parkinsonism. Ital. J. Neurol. Sci. 11, 367-372. (Pubitemid 20338622)
104. Sasaki S., Shirata A., Yamane K., and, Iwata M., (2008) Involvement of spinal motor neurons in parkin-positive autosomal recessive juvenile parkinsonism. Neuropathology 28, 74-80.
105. Schell H., Hasegawa T., Neumann M., and, Kahle P. J., (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160, 796-804.
106. Schintu N., Frau L., Ibba M., Garau A., Carboni E., and, Carta A. R., (2009) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox. Res. 16, 127-139.
107. Schneider E., Fischer P. A., Jacobi P., Becker H., and, Hacker H., (1979) The significance of cerebral atrophy for the symptomatology of Parkinson's disease. J. Neurol. Sci. 42, 187-197. (Pubitemid 9183652)
108. Schwartzman R. J., and, Alexander G. M., (1985) Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) primate model of Parkinson's disease. Brain Res. 358, 137-143. (Pubitemid 16184083)
109. Sherer T. B., Betarbet R., Testa C. M., et al. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23, 10756-10764. (Pubitemid 37499681)
110. Shirakashi Y., Kawamoto Y., Tomimoto H., Takahashi R., and, Ihara M., (2006) alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Acta Neuropathol. 112, 681-689. (Pubitemid 44615029)
111. Sotiriou E., Vassilatis D. K., Vila M., and, Stefanis L., (2010) Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol. Aging 31, 2103-2114.
112. Srinivasan J., and, Schmidt W. J., (2003) Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine- induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17, 2586-2592. (Pubitemid 36819283)
113. Srinivasan J., and, Schmidt W. J., (2004) Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav. Brain Res. 154, 353-363. (Pubitemid 39093986)
114. Tarohda T., Ishida Y., Kawai K., Yamamoto M., and, Amano R., (2005) Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal. Bioanal. Chem. 383, 224-234. (Pubitemid 41442914)
115. Taylor T. N., Caudle W. M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G., and, Miller G. W., (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
116. Taylor T. N., Caudle W. M., and, Miller G. W., (2011) VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011, 124165.
117. Threlfell S., Exley R., Cragg S. J., and, Greenfield S. A., (2008) Constitutive histamine H2 receptor activity regulates serotonin release in the substantia nigra. J. Neurochem. 107, 745-755.
118. Truong D. D., and, Wolters E. C., (2009) Recognition and management of Parkinson's disease during the premotor (prodromal) phase. Expert Rev. Neurother. 9, 847-857.
119. Truong L., Allbutt H. N., Coster M. J., Kassiou M., and, Henderson J. M., (2009) Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res. Bull. 78, 91-96.
120. Turner M. S., Gray T. S., Mickiewicz A. L., and, Napier T. C., (2008) Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions. Brain Struct. Funct. 213, 197-213.
121. Ullrich C., and, Humpel C., (2009) Rotenone induces cell death of cholinergic neurons in an organotypic co-culture brain slice model. Neurochem. Res. 34, 2147-2153.
122. Vernon A. C., Crum W. R., Johansson S. M., and, Modo M., (2011) Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One 6, e17269.
123. Vivacqua G., Yin J. J., Casini A., Li X., Li Y. H., D'Este L., Chan P., Renda T. G., and, Yu S., (2009) Immunolocalization of alpha-synuclein in the rat spinal cord by two novel monoclonal antibodies. Neuroscience 158, 1478-1487.
124. Vivacqua G., Casini A., Vaccaro R., Fornai F., Yu S., and, D'Este L., (2011a) Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies. J. Chem. Neuroanat. 41, 97-110.
125. Vivacqua G., Casini A., Vaccaro R., Salvi E. P., Pasquali L., Fornai F., Yu S., and, D'Este L., (2011b) Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. J. Chem. Neuroanat. [Epub ahead of print].
126. Wakabayashi K., and, Takahashi H., (1997) The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol. 94, 287-289. (Pubitemid 27395331)
127. Wang S., Yan J. Y., Lo Y. K., Carvey P. M., and, Ling Z., (2009a) Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res. 1265, 196-204.
128. Wang T., Zhang Q. J., Liu J., Wu Z. H., and, Wang S., (2009b) Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci. Bull. 25, 15-20.
129. Wang Y., Zhang Q. J., Liu J., Ali U., Gui Z. H., Hui Y. P., Chen L., Wu Z. H., and, Li Q., (2010a) Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res. 1310, 189-199.
130. Wang Y., Zhang Q. J., Liu J., Ali U., Gui Z. H., Hui Y. P., Wang T., Chen L., and, Li Q., (2010b) Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of alpha2-adrenoceptors in normal and medial forebrain bundle lesioned rats. Brain Res. 1324, 64-74.
131. Willis G. L., and, Sandyk R., (1992) Sensitivity of dopamine receptors in the lateral hypothalamus is altered in 6-hydroxydopamine treated rats. Int. J. Neurosci. 65, 199-207.
132. Wolters E., (2009) Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 15 (Suppl 3), S6-S12.
133. Zarow C., Lyness S. A., Mortimer J. A., and, Chui H. C., (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341. (Pubitemid 36314358)
134. Zweig R. M., Cardillo J. E., Cohen M., Giere S., and, Hedreen J. C., (1993) The locus ceruleus and dementia in Parkinson's disease. Neurology 43, 986-991. (Pubitemid 23150574)